This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry
by Zacks Equity Research
Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.
Globus Medical Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Globus Medical (GMED) is optimistic about sustaining its growth momentum on recent positive developments.
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight
by Zacks Equity Research
This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.
NUVA vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUVA vs. HAE: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth
by Zacks Equity Research
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
Amedisys (AMED) Benefits From Home Health and Personal Care
by Zacks Equity Research
Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
NuVasive Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.
TransMedics' OCS Technology Sees Success in Heart Transplant
by Zacks Equity Research
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.
NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell to Feature Upgrades in Medication Management at ASHP
by Zacks Equity Research
Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.
Boston Scientific's Watchman Implant Study Results Encourage
by Zacks Equity Research
These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.
NuVasive Advances on Global Footprint Despite Pricing Woes
by Zacks Equity Research
Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.
Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits
by Zacks Equity Research
Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.
Haemonetics (HAE) Launches SafeTrace Tx in North America
by Zacks Equity Research
Haemonetics (HAE) expands the transfusion management portfolio with SafeTrace Tx, the latest in its transfusion management software product line.
Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries
by Zacks Equity Research
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Thermo Fisher Rides on New Product Suite and Global Growth
by Urmimala Biswas
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
ViewRay Allies With Two Majors in MR-Guided Radiation Therapy
by Zacks Equity Research
ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.
RadNet Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.
Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA
by Zacks Equity Research
Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.
CVS Health Set to Acquire Centene's IlliniCare Health Plan
by Zacks Equity Research
CVS Health's (CVS) latest collaboration with Centene is set to expand its Medicaid and Medicare Advantage presence in Illinois.
BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
by Zacks Equity Research
BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its stellar performance.
Intuitive (ISRG) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Intuitive Surgical (ISRG) has been gaining from a series of positive developments of late.
Why Is Haemonetics (HAE) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.